{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:08:56Z","timestamp":1790125736532,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40265-025-02219-4","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T14:17:26Z","timestamp":1753885046000},"page":"1093-1098","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?"],"prefix":"10.1007","volume":"85","author":[{"given":"Tulsi","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8106-4927","authenticated-orcid":false,"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"issue":"1","key":"2219_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"T Steiner","year":"2020","unstructured":"Steiner T, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world\u2019s causes of disability, and first among young women: Findings from GBD2019. J Headache Pain. 2020;21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0.","journal-title":"J Headache Pain"},{"key":"2219_CR2","unstructured":"HIS Classification ICHD-3. Migraine without aura. https:\/\/ichd-3.org\/1-migraine\/1-1-migraine-without-aura\/. Accessed 11 February 2025."},{"issue":"Suppl 1","key":"2219_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/head.13301","volume":"58","author":"R Agosti","year":"2018","unstructured":"Agosti R. Migraine burden of disease: from the patient\u2019s experience to a socio-economic view. Headache. 2018;58(Suppl 1):17\u201332. https:\/\/doi.org\/10.1111\/head.13301.","journal-title":"Headache"},{"issue":"9","key":"2219_CR4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/03331024211006048","volume":"41","author":"H Pohl","year":"2021","unstructured":"Pohl H, Benemei S, Garcia-Azorin D, Dixon J, Huzzey E, Ferrari MD. Time lost due to an attack - a novel patient-reported outcome measure for acute migraine treatments. Cephalalgia. 2021;41(9):1027\u201332. https:\/\/doi.org\/10.1177\/03331024211006048.","journal-title":"Cephalalgia"},{"issue":"S1","key":"2219_CR5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/head.13300","volume":"58","author":"DW Dodick","year":"2018","unstructured":"Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache J Head Face Pain. 2018;58(S1):4\u201316. https:\/\/doi.org\/10.1111\/head.13300.","journal-title":"Headache J Head Face Pain."},{"issue":"3","key":"2219_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/wco.0000000000000310","volume":"29","author":"P Bose","year":"2016","unstructured":"Bose P, Goadsby PJ. The migraine postdrome. Curr Opin Neurol. 2016;29(3):299\u2013301. https:\/\/doi.org\/10.1097\/wco.0000000000000310.","journal-title":"Curr Opin Neurol"},{"key":"2219_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10194-016-0599-8","volume":"17","author":"C Lampl","year":"2016","unstructured":"Lampl C, Thomas H, Stovner LJ, Tassorelli C, Katsarava Z, La\u00ednez JM, Lant\u00e9ri-Minet M, Rastenyte D, Ruiz de la Torre E, Andr\u00e9e C, Steiner TJ. Interictal burden attributable to episodic headache: findings from the Eurolight project. J Headache Pain. 2016;17:9. https:\/\/doi.org\/10.1186\/s10194-016-0599-8.","journal-title":"J Headache Pain"},{"issue":"5","key":"2219_CR8","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/head.14460","volume":"63","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Buse DC, Sandoe CH, Ford JH, Hand AL, Jedynak JP, Port MD, Detke HC. Changes in migraine interictal burden following treatment with galcanezumab: results from a phase III randomized, placebo-controlled study. Headache. 2023;63(5):683\u201391. https:\/\/doi.org\/10.1111\/head.14460.","journal-title":"Headache"},{"key":"2219_CR9","unstructured":"HIS Classification ICHD-3. Definition of terms. https:\/\/ichd-3.org\/definition-of-terms\/. Accessed 11 Feb 2025."},{"key":"2219_CR10","doi-asserted-by":"publisher","first-page":"1496401","DOI":"10.3389\/fneur.2024.1496401","volume":"15","author":"L Gao","year":"2024","unstructured":"Gao L, Zhao F, Tu Y, Liu K. The prodrome of migraine: mechanistic insights and emerging therapeutic strategies. Front Neurol. 2024;15:1496401. https:\/\/doi.org\/10.3389\/fneur.2024.1496401.","journal-title":"Front Neurol"},{"issue":"6","key":"2219_CR11","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1212\/01.wnl.0000052998.58526.a9","volume":"60","author":"NJ Giffin","year":"2003","unstructured":"Giffin NJ, Ruggiero L, Lipton RB, Silberstein SD, Tvedskov JF, Olesen J, Altman J, Goadsby PJ, Macrae A. Premonitory symptoms in migraine. Neurol. 2003;60(6):935\u201340. https:\/\/doi.org\/10.1212\/01.wnl.0000052998.58526.a9.","journal-title":"Neurol"},{"issue":"2","key":"2219_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1046\/j.1468-2982.2000.00030.x","volume":"20","author":"R Luciani","year":"2000","unstructured":"Luciani R, Carter D, Mannix L, Hemphill M, Diamond M, Cady R. Prevention of migraine during prodrome with naratriptan. Cephalalgia. 2000;20(2):122\u20136. https:\/\/doi.org\/10.1046\/j.1468-2982.2000.00030.x.","journal-title":"Cephalalgia"},{"issue":"31\u201332","key":"2219_CR13","first-page":"914","volume":"79","author":"G Jenzer","year":"1990","unstructured":"Jenzer G, Bremgartner MF. Dihydroergotamine as a nasal spray in the therapy of migraine attacks, efficacy and tolerance. Schweiz Rundsch Med Prax. 1990;79(31\u201332):914\u20137.","journal-title":"Schweiz Rundsch Med Prax"},{"issue":"7","key":"2219_CR14","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40263-024-01091-2","volume":"38","author":"N Karsan","year":"2024","unstructured":"Karsan N, Goadsby PJ. Intervening in the premonitory phase to prevent migraine: prospects for pharmacotherapy. CNS Drugs. 2024;38(7):533\u201346. https:\/\/doi.org\/10.1007\/s40263-024-01091-2.","journal-title":"CNS Drugs"},{"issue":"6 Suppl","key":"2219_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1177\/03331024870070s6195","volume":"7","author":"H Massiou","year":"1987","unstructured":"Massiou H. Dihydroergotamine nasal spray in prevention and treatment of migraine attacks: two controlled trials versus placebo. Cephalalgia. 1987;7(6 Suppl):440\u20131. https:\/\/doi.org\/10.1177\/03331024870070s6195.","journal-title":"Cephalalgia"},{"issue":"1","key":"2219_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10194-023-01560-x","volume":"24","author":"S Ashina","year":"2023","unstructured":"Ashina S, Melo-Carrillo A, Toluwanimi A, Bolo N, Szabo E, Borsook D, Burstein R. Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders. J Headache Pain. 2023;24(1):26. https:\/\/doi.org\/10.1186\/s10194-023-01560-x.","journal-title":"J Headache Pain"},{"issue":"10419","key":"2219_CR17","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/s0140-6736(23)01683-5","volume":"402","author":"DW Dodick","year":"2023","unstructured":"Dodick DW, Goadsby PJ, Schwedt TJ, Lipton RB, Liu C, Lu K, Yu SY, Severt L, Finnegan M, Trugman JM. Ubrogepant for the treatment of migraine attacks during the Prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA. Lancet. 2023;402(10419):2307\u201316. https:\/\/doi.org\/10.1016\/s0140-6736(23)01683-5.","journal-title":"Lancet"},{"issue":"1","key":"2219_CR18","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200359","volume":"15","author":"TJ Schwedt","year":"2025","unstructured":"Schwedt TJ, Lipton RB, Goadsby PJ, Chiang CC, Klein BC, Hussar C, Liu C, Yu SY, Finnegan M, Trugman JM. Characterizing prodrome (premonitory phase) in migraine: results from the PRODROME trial screening period. Neurol Clin Pract. 2025;15(1): e200359. https:\/\/doi.org\/10.1212\/CPJ.0000000000200359.","journal-title":"Neurol Clin Pract."},{"issue":"7","key":"2219_CR19","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/s41591-025-03679-7","volume":"31","author":"PJ Goadsby","year":"2025","unstructured":"Goadsby PJ, Ailani J, Dodick DW, et al. Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial. Nat Med. 2025;31(7):2179\u201385. https:\/\/doi.org\/10.1038\/s41591-025-03679-7.","journal-title":"Nat Med"},{"issue":"6","key":"2219_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209745","volume":"103","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Harriott AM, Ma JY, Smith JH, Stokes J, Gandhi P, Jariwala-Parikh K, Jensen GS, Trugman JM, Dodick DW. Effect of ubrogepant on patient-reported outcomes when administered during the migraine prodrome: results from the randomized PRODROME trial. Neurol. 2024;103(6): e209745. https:\/\/doi.org\/10.1212\/WNL.0000000000209745.","journal-title":"Neurol"},{"issue":"4","key":"2219_CR21","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/head.14479","volume":"63","author":"M Graf","year":"2023","unstructured":"Graf M, Kim E, Brewer I, Hernandez J, Chou JW, Cirillo J, Jensen C, Lipton R. Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi Panel. Headache J Head Face Pain. 2023;63(4):506\u201316. https:\/\/doi.org\/10.1111\/head.14479.","journal-title":"Headache J Head Face Pain."},{"issue":"1","key":"2219_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/head.13203","volume":"58","author":"EM Lichten","year":"2018","unstructured":"Lichten EM. Menstrual migraine and treatment options: Review. Headache J Head Face Pain. 2018;58(1):145\u20136. https:\/\/doi.org\/10.1111\/head.13203.","journal-title":"Headache J Head Face Pain."},{"issue":"11","key":"2219_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1468-2982.2009.01840.x","volume":"29","author":"JL Brandes","year":"2009","unstructured":"Brandes JL, Poole AC, Kallela M, Schreiber CP, MacGregor EA, Silberstein SD, Tobin J, Shaw R. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia. 2009;29(11):1133\u201348. https:\/\/doi.org\/10.1111\/j.1468-2982.2009.01840.x.","journal-title":"Cephalalgia"},{"issue":"2","key":"2219_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1212\/01.wnl.0000134620.30129.d6","volume":"63","author":"SD Silberstein","year":"2004","unstructured":"Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004;63(2):261\u20139. https:\/\/doi.org\/10.1212\/01.wnl.0000134620.30129.d6.","journal-title":"Neurology"},{"issue":"10","key":"2219_CR25","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/head.14828","volume":"64","author":"OA Almohammed","year":"2024","unstructured":"Almohammed OA, Alsanea S, Albishi N, AlMuhareb L, AlMotawa R, Alrasheed S, Alasmari F, Almutairi F, Assiri MA, Alghamdi A, Albilali A, ElToukhy A, R, Alwhaibi A,. Evaluating the use of paracetamol to prevent fasting headache during the first week of Ramadan: A randomized, open-label, clinical trial. Headache. 2024;64(10):1285\u201397. https:\/\/doi.org\/10.1111\/head.14828.","journal-title":"Headache"},{"key":"2219_CR26","unstructured":"Alsaadi T, Suliman R, Yang J, et al. Efficacy and safety of rimegepant for the preventive treatment of fasting-related headache during Ramadan in the UAE [ePoster]. European Headache Federation Conference; 2024 December 4-7; Rotterdam. https:\/\/programme.conventus.de\/ehc-2024\/program\/program-points\/c8d7388b-5fc6-4f6f-96c8-086e06fecd63. Accessed 12 Feb 2025."},{"issue":"3","key":"2219_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1526-4610.2010.01827.x","volume":"51","author":"M Latsko","year":"2011","unstructured":"Latsko M, Silberstein S, Rosen N. Frovatriptan as preemptive treatment for fasting-induced migraine. Headache. 2011;51(3):369\u201374. https:\/\/doi.org\/10.1111\/j.1526-4610.2010.01827.x.","journal-title":"Headache"},{"issue":"7","key":"2219_CR28","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/head.14775","volume":"64","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Ailani J, Mullin K, Pavlovic JM, Tepper SJ, Dodick DW, Blumenfeld AM. Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks. Headache J Head Face Pain. 2024;64(7):859\u201364. https:\/\/doi.org\/10.1111\/head.14775.","journal-title":"Headache J Head Face Pain."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02219-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02219-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02219-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:17:55Z","timestamp":1757258275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02219-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["2219"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02219-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"22 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tulsi Shah has no conflicts of interest. Jessica Ailani has received honoraria for independent consulting and\/or participating on advisory boards from AbbVie, Amneal Pharmaceuticals, Aspya, Bausch, Dr. Reddy, Eli Lilly and Company, Pfizer, Lundbeck, Satsuma, Aeon, Ipsen, and Merz; clinical trial grants (fees to institution) from Parema, Ipsen, Lundbeck, Shira-Tronic, and Pfizer; clinical trial grants (fees to principal investigator) from Mi-Helper; and editorial services for SELF magazine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"JA and TS were responsible for the manuscript design, write-up, editing, and review and approval. Both authors read and approved the final version of this manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}